PTEN, ARID1A, CTNNB1, PIK3CA, and KRAS mutations commonly occur in type I EC [24,25], whereas TP53 mutations are frequent in type II (90%) and associated with serous carcinoma and endometrial intraepithelial carcinoma [26,27]. This evidence concerns the gene ARID1A and serous adenocarcinoma.